Share on LinkedInShare on LinkedIn

ARTICLE · 17 MAY 2016

BRPTO Stands Up To ANVISA For Pharmaceuticals

As you already know, for the allowance of pharmaceutical patents, the Brazilian IP Law currently requires the prior consent from ANVISA (Brazilian Health Surveillance Agency – equivalent to American FDA) along with the usual examination from the BRPTO.

BrazilIntellectual Property

As you already know, for the allowance of pharmaceutical patents, the Brazilian IP Law currently requires the prior consent from ANVISA (Brazilian Health Surveillance Agency – equivalent to American FDA) along with the usual examination from the BRPTO. It has been a while that both federal authorities dispute for the role of examining patents, which led to a double tier examination procedure.

The current flow established by Ordinance 1065 of May 25, 2012 developed by a Working Group formed by several Brazilian Ministries states that a pharmaceutical application should be sent to ANVISA for prior consent before being evaluated by BRPTO and, in case ANVISA denies the prior consent, that this application should be returned to the BRPTO in order to be shelved.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from